Pancreatic Cancer Research

ResearcherInstitute of Science TokyoActive in the last 2 years

Toshitaka Sugawara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7211-6094; OpenAlex author ID A5067267220. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 6 papers · 2025: 2 papers · 2026: 6 papers

Papers 19

  1. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  2. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Co-author DOI 10.1016/j.hpb.2026.04.451↗
  3. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.12.007↗
  4. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  5. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  6. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  7. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. First author DOI 10.1001/jamaoncol.2024.5917↗
  8. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  9. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  10. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Co-author DOI 10.1016/j.pan.2024.11.011↗
  11. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Co-author DOI 10.1097/sla.0000000000005925↗
  12. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy. First author DOI 10.1245/s10434-024-15157-4↗
  13. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemothera… Co-author DOI 10.1245/s10434-024-15443-1↗
  14. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection. Co-author DOI 10.1245/s10434-024-15975-6↗
  15. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1001/jamaoncol.2022.5808↗
  16. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  17. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.05.008↗
  18. Advances in the management of pancreatic cancer. First author DOI 10.1136/bmj-2022-073995↗
  19. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Co-author DOI 10.1371/journal.pone.0249885↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 13 shared papers, 2023–2026 · strength 2.69
  2. Marco Del Chiaro · 11 shared papers, 2023–2026 · strength 2.29
  3. Oskar Franklin · 10 shared papers, 2024–2026 · strength 2.22
  4. Thomas F. Stoop · 6 shared papers, 2023–2026 · strength 1.35
  5. Ana Gleisner · 5 shared papers, 2023–2026 · strength 1.02
  6. Wells A. Messersmith · 4 shared papers, 2023–2026 · strength 0.89
  7. Jun Ishida · 4 shared papers, 2023–2026 · strength 0.84
  8. Samuele Grandi · 4 shared papers, 2023–2026 · strength 0.84
  9. Hiroyuki Ishida · 3 shared papers, 2026 · strength 0.75
  10. Marco Del Chiaro · 3 shared papers, 2024–2026 · strength 0.66
  11. Asif Halimi · 3 shared papers, 2026 · strength 0.66
  12. Robert J. Torphy · 3 shared papers, 2024 · strength 0.58
  13. Yosuke Inoue · 3 shared papers, 2023–2026 · strength 0.50
  14. Atsushi Oba · 3 shared papers, 2023–2026 · strength 0.50
  15. Marc G. Besselink · 3 shared papers, 2023–2026 · strength 0.50
  16. Sana D. Karam · 2 shared papers, 2023–2024 · strength 0.49
  17. Adrienne Molnár · 2 shared papers, 2026 · strength 0.47
  18. Martin M. McCarter · 2 shared papers, 2024 · strength 0.39
  19. Elliott J. Yee · 2 shared papers, 2024 · strength 0.39
  20. Freek D. Daams · 2 shared papers, 2026 · strength 0.37
  21. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.37
  22. Ernesto Sparrelid · 2 shared papers, 2026 · strength 0.37
  23. Bas Groot Koerkamp · 2 shared papers, 2026 · strength 0.37
  24. Poya Ghorbani · 2 shared papers, 2026 · strength 0.37
  25. Roeland F. de Wilde · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.